Jw Holdings (096760) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Jw Holdings stock KRW 10,995, price KRW 3,665, upside +200.0%, quality 61 out of 100. Rating: strongly undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
60‑month range 2,324 KRW – 4,390 KRW · fair‑value band 6,949 KRW – 15,385 KRW · the 3,665 KRW price screens below the 10,995 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.
Follow Jw in your weekly email
Every Wednesday you see whether Jw is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
JW Holdings Corporation, together with its subsidiaries, operates as a healthcare company in South Korea, the United States, Japan, China, and internationally.
Show moreShow less
The company offers amino acid solutions, gastrointestinal agents, wound care, eye care, liver disease treatment, cold medicine, API, oral and topical analgesic, and other miscellaneous pharmaceutical products.
It also offers hairdye, hair care, beauty care, and other cosmetics products; infant care system, gynecological examining table, sterilizer equipment, diagnostic imaging equipment, operating room equipment, non-PVC film, tube, and empty bag, and health supplements.
In addition, the company provides integrated services for IV solution. JW Holdings Corporation was founded in 1945 and is based in Gwacheon-si, South Korea.
Stock analysis
Jw Holdings (096760) currently trades at 3,665 KRW, while our model-based Fair Value estimate is 10,995 KRW, implying the stock looks roughly 67% undervalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 16,488 KRW per share, and 22 of the 26 models we run sit above the 3,665 KRW price.
Bear case: the Dividend Discount group reads lowest at 1,608 KRW, and 4 of the 26 models stay below the price. Data coverage for this calculation is low.
Scenario range: 6,949 KRW (bear) to 15,385 KRW (bull), the price of 3,665 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 61/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Jw Holdings reported revenue of 970B KRW in FY2025 versus 789B KRW in FY2021, a compound +5.3%/yr. Reported net income was 58.5B KRW in FY2025.
Key figures
Market cap 254B KRW (≈ $187M) Micro · P/E ratio 2.9 · P/S ratio 0.25 · EPS (TTM) 1,221 KRW · Dividend yield 5.9% · Net margin 8.4% · Return on equity 26.8% · Return on assets (EBIT) 10.8% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 63 out of 100 (low confidence).
What moves the price
The share trades about 17% below its 52-week high and 13% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 200%, 096760 screens cheaper than that median.
Fair Value models
Bear6,949 KRWFair Value 10,995 KRWBull15,385 KRW
Price 3,665 KRW · Upside +200.0%
Capped: our models arrive at a very high value here. We deliberately show a more cautious Fair Value.
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (862.50 KRW per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.72/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+9.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.4%
Start year 2020 (pandemic). Over 10 years: +4.5% a year
Revenue growth 18 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.1%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
≈ +42.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year+36.1%
Dividend (yield on the price)5.9%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.4% → 17%
⚠ Rate on operating basis: 2025 sits 176% above its own trend.
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−13.1%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about −14.9% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks
Beats the industry median on 13/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score61 · Above median
Fair Value upside+200.0% · Top 25%
Profitability
Return on equity (12 months)26.8% · Top 25%
Return on assets9.4% · Top 25%
Net margin (12 months)16.5% · Top 25%
Operating margin (12 months)20.2% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)16.7% · Above median
Dividend yield (12 months)5.9% · Top 25%
Balance sheet
Debt / equity0.31× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Jw Holdings Fair Value". https://www.fairvalue-calculator.com/stock/096760
Frequently asked questions
Is Jw Holdings (096760) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of 10,995 KRW versus a price of 3,665 KRW, about +200% upside (undervalued).
What is the fair value of 096760?
Our model-based fair value for Jw Holdings is 10,995 KRW (as of Nov 6, 2026), built from audited fundamentals. The current price: 3,665 KRW.
What is the quality score of 096760?
Jw Holdings has a Quality Score of 61/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Jw Holdings (096760)?
Our model-based price target is the fair value of 10,995 KRW (as of Nov 6, 2026) from 26 valuation models. Cautious scenario 6,949 KRW, optimistic scenario 15,385 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Jw Holdings stock forecast for 2026?
Our models put fair value at 10,995 KRW, about +200% upside versus a price of 3,665 KRW (undervalued). Cautious scenario 6,949 KRW, optimistic scenario 15,385 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Jw Holdings (096760)?
Jw Holdings reported trailing-twelve-month revenue of about 1.0T KRW (latest available figure, as of Nov 6, 2026).
Does Jw Holdings pay a dividend?
Jw Holdings currently shows a dividend yield of 5.87% relative to its recent price (as of Nov 6, 2026).
How much is the dividend of Jw Holdings (096760) and when is the ex-dividend date?
Jw Holdings pays a dividend of 215.00 KRW per share a year, a dividend yield of 5.9%. The last ex-dividend date was Mar 31, 2026. The payout ratio is 17.6% of earnings. Free cash flow covers the dividend 7.33 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Jw Holdings (096760)?
For today's price to be fair in a discounted-cash-flow model, Jw Holdings would have to grow free cash flow by -13.1 % per year for five years (discount rate 11.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +4.4 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of 096760 use?
Our models discount Jw Holdings at 11.7 %: a base by market capitalisation (micro), damped by beta 0.56, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Jw Holdings that is -13.1 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.7 %) and the same formula as our fair value.
How much growth has Jw Holdings (096760) delivered so far?
Over the past 5 years revenue at Jw Holdings grew +4.4 % a year. The price currently implies free-cash-flow growth of -13.1 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Jw Holdings (096760) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Jw Holdings (-13.1 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Jw Holdings (096760)?
The free-cash-flow yield on the price is 42.97 %: that much free cash flow Jw Holdings produces per unit of market value. When it exceeds the discount rate of our models (11.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Jw Holdings (096760)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Jw Holdings it is 10,995 KRW per share (as of Nov 6, 2026), against a price of 3,665 KRW. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Jw Holdings stock overvalued or undervalued in 2026?
As of Nov 6, 2026, 096760 trades below its calculated fair value: price 3,665 KRW, fair value 10,995 KRW, a gap of about +200% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 096760?
No. The price is what the market pays today (3,665 KRW); the fair value is what the company's own numbers justify (10,995 KRW). For Jw Holdings the two are 7,330 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Jw Holdings worth?
The market values Jw Holdings at about 254B KRW (market capitalisation, as of Nov 6, 2026). Per share that is 3,665 KRW; our models calculate a fair value of 10,995 KRW per share.
What do the bullish and bearish scenarios say about 096760?
Our models span a range for Jw Holdings: cautious scenario 6,949 KRW, base 10,995 KRW, optimistic 15,385 KRW per share (as of Nov 6, 2026, price 3,665 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 096760?
Jw Holdings trades at a price-to-earnings ratio of 2.9 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 10,995 KRW is built from several models across several years. Other multiples: P/B 1.0, P/S 0.5, EV/EBITDA 2.3.
How solid is the balance sheet of Jw Holdings (096760)?
Balance-sheet figures for Jw Holdings (as of Nov 6, 2026): return on equity 26.8%, debt of 0.31 per unit of equity. They feed the Quality Score of 61/100, which measures business quality independently of the share price.
How far is 096760 from its 52-week high?
Jw Holdings trades at 3,665 KRW, about 17% below its 52-week high of 4,390 KRW and 13% above the low of 3,236 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 10,995 KRW is for.
Which stocks are comparable to Jw Holdings?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Jw Holdings stock attractive at the current price?
The data as of Nov 6, 2026: price 3,665 KRW, calculated fair value 10,995 KRW (+200%), Quality Score 61/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 096760 calculated?
We run Jw Holdings through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 10,995 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Jw Holdings currently trades 67% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Jw Holdings (096760)?
The closing price on Nov 6, 2026 was 3,665 KRW. Our model-based fair value is 10,995 KRW, about +200% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Jw Holdings right now?
The price is below even our cautious bear case (6,949 KRW). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (61/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (6,949 KRW to 15,385 KRW) leaves room in how you read the outcome.
Key figures of Jw Holdings
How large is the market capitalisation of Jw Holdings (096760)?
The market capitalisation of Jw Holdings is 254B KRW (≈ $187M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Jw Holdings (096760)?
The price-to-sales ratio of Jw Holdings is 0.25 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Jw Holdings (096760)?
Earnings per share at Jw Holdings are 1,221 KRW (price ÷ EPS = P/E 2.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Jw Holdings (096760)?
The dividend yield of Jw Holdings is 5.9% (payout 17.6%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Jw Holdings (096760)?
The net margin of Jw Holdings is 8.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Jw Holdings (096760)?
The return on equity (ROE) of Jw Holdings is 26.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Jw Holdings (096760)?
On an EBIT basis the return on assets of Jw Holdings is 10.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Jw Holdings (096760)?
The operating margin of Jw Holdings is 20.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Jw Holdings (096760)?
Revenue at Jw Holdings is growing +16.7% versus a year earlier (3y avg +3.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Jw Holdings (096760)?
Earnings per share at Jw Holdings are growing +393% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Jw Holdings (096760) carry?
The net debt of Jw Holdings is 265B KRW (fiscal year 2025, ≈ 2.4 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Jw Holdings in the live analysis
One click puts Jw Holdings on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 6, 2026